RAPT Therapeutics, Inc.

MUN:0RA Stock Report

Market Cap: €158.2m

RAPT Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0RA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders668,1320.495%
Institutions40,415,11029.9%
General Public45,887,75134%
VC/PE Firms47,987,26035.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 292.4%.

Top Shareholders

Top 25 shareholders own 61.77% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.6%
Medicxi Ventures (UK) LLP
22,352,000€26.2m0%5.68%
9.73%
TCG Crossover Management, LLC
13,135,260€15.4m0%1.63%
9.26%
Foresite Capital Management, LLC
12,500,000€14.7m0%5.17%
4.45%
Deep Track Capital, LP
6,011,380€7.0m0%0.23%
4%
BVF Partners L.P.
5,401,936€6.3m0%0.22%
3.88%
FMR LLC
5,235,521€6.1m0%no data
2.34%
The Vanguard Group, Inc.
3,156,005€3.7m1.54%no data
1.85%
BlackRock, Inc.
2,498,521€2.9m2.41%no data
1.28%
Kingdon Capital Management, L.L.C.
1,725,000€2.0m0%0.31%
0.98%
The Column Group, LLC
1,328,613€1.6m-50.4%2.72%
0.78%
D. E. Shaw & Co., L.P.
1,048,186€1.2m15.5%no data
0.71%
Millennium Management LLC
959,965€1.1m-6.26%no data
0.62%
Acadian Asset Management LLC
842,157€987.4k80.3%no data
0.59%
Federated Hermes, Inc.
799,978€937.9k0.49%no data
0.52%
Two Sigma Advisers, LP
705,000€826.6k0.95%no data
0.51%
Geode Capital Management, LLC
683,179€801.0k-0.22%no data
0.5%
State Street Global Advisors, Inc.
679,508€796.7k1.15%no data
0.49%
Euclidean Capital LLC
657,899€771.3k0%0.09%
0.43%
Point72 Asset Management, L.P.
580,741€680.9k-42.8%no data
0.4%
GV Management Company, LLC
540,270€633.4k0%0.04%
0.39%
Two Sigma Investments, LP
520,422€610.2k-15%no data
0.38%
Pale Fire Capital SE
510,724€598.8k3,080%0.11%
0.37%
Redmile Group, LLC
504,532€591.5k-5.99%0.04%
0.37%
Cormorant Asset Management, LP
496,750€582.4k0%0.04%
0.37%
Brian Wong
492,618€577.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 00:21
End of Day Share Price 2024/11/04 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RAPT Therapeutics, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leon WangBarclays
Gao Yi ChenBerenberg
Guyn KimBMO Capital Markets Equity Research